Add-On Ibrutinib Slows Mantle-Cell Lymphoma in Older Adults
Addition of ibrutinib to chemoimmunotherapy prolongs progression-free survival in older patients with untreated mantle-cell lymphoma
Non-Hodgkin Lymphoma
Survival Up With Bortezomib in T-Cell Lymphoblastic Lymphoma
No differences in EFS or OS seen with/without bortezomib overall or in patients with T-cell acute lymphoblastic leukemia
Incyte Withdraws Parsaclisib NDA for Follicular, Marginal Zone, and Mantle Cell Lymphomas
Parsaclisib is an investigational, highly selective, oral inhibitor of phosphatidylinositol 3-kinase delta.
Parsaclisib Under Review for Follicular, Marginal Zone, and Mantle Cell Lymphomas
The application is supported by data from several phase 2 studies.
New C-CAR039 Therapy Is Safe and Effective in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Researchers sought to determine whether C-CAR039 would be safe and effective in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
Significant reduction found in risk for disease progression/death for C+R versus placebo and rituximab
